Skip to main content
. 2018 Apr 25;8(2):312–319. doi: 10.1016/j.ijpddr.2018.04.006

Fig. 4.

Fig. 4

ugt-22 mutation and overexpression alter albendazole efficacy. (A) Percent long-term spontaneous motility of adult wild type (N2) and ugt-22(gk411724lf) (lf, loss-of-function) mutant worms exposed to 2.5 μM albendazole for 3 days. (B) Percent long-term spontaneous motility of three independently generated ugt-22 gDNA extrachromosomal array lines in the ugt-22(gk411724lf) genetic background exposed to 11 μM albendazole for 3 days. Motility of all three ugt-22 gDNA array lines was greater than wild type worms (N2) (9.4%) and comparable to skn-1(k1023gf) worms (40.5%) (values are from Fig. 1). (C) Relative mRNA levels of ugt-22 in control and ugt-22 transgenic lines. (D) Percent spontaneous motility of adult transgenic control and ugt-22 overexpression (OE) lines exposed to 11 μM albendazole for 3 days. Motility of ugt-22 overexpression transgenic lines was greater than skn-1(k1023gf) worms (40.5%) (value is from Fig. 1). **P<0.01, ***P<0.001 relative to respective control worms; ns = not statistically significant. n = 79–278 worms per strain in (A–B) and three independent transgenic lines in (C–D) with 78–111 worms tested per line.